News & Updates
Filter by Specialty:
Beta-blocker shows potential for diabetic foot ulcers
20 Oct 2022
byAudrey Abella
A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).
Beta-blocker shows potential for diabetic foot ulcers
20 Oct 2022
Metformin plus R-form verapamil improves glycaemic control in T2D
19 Oct 2022
byStephen Padilla
Combination therapy with metformin plus R-form verapamil (R-Vera) leads to significant improvements in glycaemic control by reducing haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients with type 2 diabetes (T2D), reports a study.
Metformin plus R-form verapamil improves glycaemic control in T2D
19 Oct 2022
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
19 Oct 2022
byAudrey Abella
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
